Država: Kanada
Jezik: engleski
Izvor: Health Canada
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE
SEPTODONT INC
N01BB51
BUPIVACAINE, COMBINATIONS
5MG; 0.0091MG
SOLUTION
BUPIVACAINE HYDROCHLORIDE 5MG; EPINEPHRINE BITARTRATE 0.0091MG
BLOCK/INFILTRATION
1.8ML
Ethical
LOCAL ANESTHETICS
Active ingredient group (AIG) number: 0231290002; AHFS:
APPROVED
2018-03-26
_Novocol Pharmaceutical of Canada, Inc. _ Page 1 of 23 PRODUCT MONOGRAPH MARCAINE® (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP) BUPIVACAINE HYDROCHLORIDE 0.5% AND EPINEPHRINE 1:200,000 _Local Anaesthetic for Dental Use _ _ _ _ _ _ _ _ _ _ _ _ _ Sponsor: Manufacturer: Septodont Inc Novocol Pharmaceutical of Canada, Inc. 25 Wolseley Court 25 Wolseley Court, Cambridge, Ontario, Cambridge, Ontario, N1R 6X3 N1R 6X3 Date of Revision: March 26, 2018 Submission Control No.: 213506 _Novocol Pharmaceutical of Canada, Inc. _ Page 2 of 23 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................................................... 3 CONTRAINDICATIONS ............................................................................................................................... 3 WARNINGS AND PRECAUTIONS. ............................................................................................................ 4 ADVERSE REACTIONS ............................................................................................................................... 7 DRUG INTERACTIONS ................................................................................................................................ 8 DOSAGE AND ADMINISTRATION ............................................................................................................ 9 OVERDOSAGE ............................................................................................................................................ 11 ACTION AND CLINICAL PHARMACOLOGY ........................................................................................ 13 STORAGE AND STABILITY ............................................................... Pročitajte cijeli dokument